## PATIENT SAFETY CARD

## IMPORTANT INFORMATION FOR PATIENTS TAKING SOLIRIS® (ECULIZUMAB FOR INJECTION)

SOLIRIS<sup>®</sup> lowers the ability of your immune system to fight infection, which increases the risk of serious infections. This includes meningococcal infections, which can quickly cause death, deafness, brain damage and/or loss of limbs, especially if not recognized and treated early.

If you experience any of the following symptoms, you should **immediately** inform your doctor:

- Headache with nausea or vomiting
- Headache and a fever
- Headache with a stiff neck or stiff back
- Fever
- Fever and a rash
- Confusion
- Muscle aches with flu-like symptoms
- Eyes sensitive to light



Immediately seek medical care if you identify/experience any listed symptoms.

You should always carry this card with you during treatment and for 3 months after your last dose of SOLIRIS<sup>®</sup>. Show it to any healthcare professional you see during this time.

## PATIENT SAFETY CARD

## IMPORTANT INFORMATION FOR THE TREATING PHYSICIAN



This patient has been prescribed SOLIRIS<sup>®</sup> (eculizumab for injection) therapy, which increases their susceptibility to meningococcal infection (*Neisseria meningitidis*) or other general infections.

- Meningococcal infections may become rapidly life-threatening or fatal if not recognized and treated early.
- All patients must be monitored for early signs of meningococcal infections, evaluated immediately if infection is suspected, and treated with antibiotics, if necessary.
- Contact the prescribing physician (see below) as soon as possible.

For more information about SOLIRIS<sup>®</sup>, please refer to the Product Monograph.

In case of safety concerns, call toll-free at: 1.888.SOLIRIS (1.888.765.4747).



ALEXION®, SOLIRIS®, and the Alexion logo are registered trademarks of Alexion Pharmaceuticals, Inc. Copyright ©2019, Alexion Pharmaceuticals, Inc. All rights reserved. SOL\_CRMP1.0\_PTSAFCD\_CA\_16012020

M/CA/SOL-g/0003E